44 results about "Hyperhomocysteinemia" patented technology

The present invention relates to the treatment of a wide array of diseases and physiologic conditions based on modulating the level of hydrogen sulfide (H2S) in the body by at least partially eradicating small intestinal bacterial overgrowth (SIBO) in the gut. An H2S or lactulose breath test and/or detection of H2S or thiosulfate in the blood or urine may be used as a diagnostic and/or prognostic for assessing a systemic H2S load that exceeds a mammal's natural detoxification capacity. These tests may similarly be used to monitor the effectiveness of a therapeutic intervention for SIBO and/or the diseases or physiologic conditions whose pathology is linked thereto. Because SIBO is related to hyperhomocysteinemia, diseases and physiologic conditions that relate to hyperhomocysteinemia may further be monitored and treated in connection with the methods of the present invention.

A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.

A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety, depression, neurodegenerative disorders (such as but not limited to Alzheimers), and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and B vitamins which together effectively lower the risk of heart disease. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to B vitamins.

The invention relates to an oral folacin pill preparation which contains drug and expients; wherein the drug contains folacin and the excipient is one of or mixture of more than two (including two) of polyethyleneglycol, magnesium stearate, stearic acid, sodium stearate, poloxamer, polyoxyethylene dehydrous sorbitol fatty acid ester, polyoxyethylene (40) monostearate (S-40), sucrose fatty ester and glycerogelatin. The invention also relates to the preparation method of the folacin pill preparation and the purpose of the folacin pill preparation in preparation of drug for treating hyperhomocysteinemia. The folacin pill preparation provided in the invention, belonging to the pharmaceutical field has the advantages of full dissolution of the drug, quick effect and improvement of human bioavailability.

The invention provides a combined medicine containing metformin hydrochloride and vitamin B12, which can prevent and treat diabetic peripheral neuropathy to the maximal extent, prevent metformin hydrochloride from inducing hyperhomocysteinemia, malabsorption of vitamin B12 to cause megaloblastic anemia, and treat aplastic anemia and the like.

The invention relates to a pharmaceutical composition for reducing homocysteine, which comprises the following components: 1) an officinal dosage of folic acid or pharmaceutical salts thereof; 2) an officinal dosage of vitamin B12 or pharmaceutical salts thereof; 3) an officinal dosage of creatine or pharmaceutical salts thereof; and 4) pharmaceutical carriers or excipients. The composition further comprises one or more than one of betaine, VB6, N-acetylcysteine, and riboflavin. The invention also relates to application of the pharmaceutical composition in preparing drugs for reducing the homocysteine as well as the application thereof in preparing the drugs for treating life bodies suffered from hyperhomocysteinemia. The pharmaceutical composition belongs to the field of pharmacy.

The invention features a novel gene encoding methionine synthase reductase. The invention also features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects, cardiovascular disease, Down's Syndrome or cancer. The invention also features therapeutic methods for treating and/or reducing the risk of cardiovascular disease, Down's Syndrome, cancer, or neural tube defects. Also provided are the sequences of the human methionine synthase reductase gene and protein and compounds and kits for performing the methods of the invention.

The invention discloses a composition. The composition comprises Radix Astragali extract, Radix Puerariae extract and white mulberry root-bark extract according to a mass ratio of (1-2):(1-2):(1-2); or the composition comprises Radix Astragali-Radix Puerariae extract and white mulberry root-bark extract, a mass ratio of Radix Astragali to Radix Puerariae in the Radix Astragali-Radix Puerariae extract is (0.5-5):1, and a mass ratio of the Radix Astragali-Radix Puerariae extract to the white mulberry root-bark extract is 1:1. The invention also discloses a preparation method and a use of the composition. The composition has the advantages of scientific and advanced preparation technology and controllable quality, has blood fat reducing, liver protecting, weight reducing and homocysteine reducing effects, can be effectively used to treat obesity induced hyperlipidemia, fatty liver, obesity and hyperhomocysteinemia, and has significant effects.

Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-γ-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.

The invention discloses a modeling feed for constructing a hyperhomocysteinemia animal model and a preparation method thereof, and relates to the technical field of construction of medicine experimental animal model. The preparation method comprises the steps: according to the proportion, weighing casein, corn starch, sucrose, cellulose, DL-methionine, L-cystine, a composite mineral, a composite vitamin and choline dihydrogen citrate, vegetable oil and water; mixing the weighed materials, stirring uniformly, preparing feed particles by a hoop standard granulator, and drying the feed particles to obtain feed particles; and finally, carrying out irradiation sterilization by using cobalt 60, to obtain the finished product. The product is formed by single stable nutrients, the nutrient composition is not affected by seasons and regions and is stable, and the processing technology at normal temperature is adopted to ensure no change of the nutrient composition of the product. The model construction success rate is high, the model preparation process is simple, and the model formation effect is good.

The invention relates to a drug composition containing indapamide and B vitamins and an application thereof in preparing drugs for treating the HHCY-hyperhomocysteinemia and the elevated homocysteine. The composition of the indapamide and B vitamins can further reduce the Hcy level, and the effect is superior to that of single drug, so that the composition of the indapamide and the B vitamins can not only lower the Hcy level, but also has synergetic effect on reducing Hcy damages. The composition of the invention is a selection for treating Hcy, which provides a more effective treatment protocol for treating high homocysteine. The invention belongs to the pharmaceutical field.

The invention discloses a method for establishing a hepatic fibrosis model through hyperhomocysteinemia induction and belongs to the field of hepatic disease research in medical science. According to the method, hyperhomocysteinemia is established through oral medication of methionine which is conducted at present, so that the mouse hepatic fibrosis model is established through induction; and then, homocysteine in blood is measured, measurement is conducted through a western blot method, masson staining conducted on tissues, and identification is conducted through an immunohistochemical method. The mouse hepatic fibrosis model established through the method is easy to operate, short in cycle and high in success rate. By means of establishment of the fibrosis model, a reliable animal model is provided for deeply researching pathogenesis of fibrosis, preliminarily screening various treatment drugs and the like.

The invention features a novel gene encoding methionine synthase reductase. The invention also features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects, cardiovascular disease, or cancer. The invention also features therapeutic methods for treating and/or reducing the risk of cardiovascular disease, cancer, or neural tube defects. Also provided are the sequences of the human methionine synthase reductase gene and protein and compounds and kits for performing the methods of the invention.

The invention discloses a glycinamide derivative, and an intermediate, a preparation method, a pharmaceutical composition and an application thereof. The invention provides the compound represented by the formula 1 or a pharmaceutically acceptable salt thereof. The invention also provides the preparation method of the compound represented by the formula 1 or the pharmaceutically acceptable salt thereof. The preparation method comprises the following steps: in a solvent and in the presence of a condensing agent and a catalyst, a compound 13 and a compound 14 undergo a condensation reaction to obtain the compound represented by the formula 1. The invention also provides the application of the compound represented by the formula 1 or the pharmaceutically acceptable salt thereof in preparation of drugs for prevention and/or treatment of diseases caused by S-adenosyl homocysteine hydrolase. The glycinamide derivative has a good inhibitory effect on S-adenosyl homocysteine hydrolase, has small toxic and side effects, can be used for preparation of the drugs for prevention and/or treatment of hyperhomocysteinemia, and has good market development prospects.

The invention discloses a use of a composition in preparing foods, medicines and health-care products for preventing or treating obesity or hyperhomocysteinemia. The composition comprises radix astragali, radix puerariae and white mulberry root bark in a mass ratio of the radix astragali to the radix puerariae to the white mulberry root bark being (1-2) to (1-2) to (0-2). According to the use disclosed by the invention, the fact that the composition comprising the radix astragali, the radix puerariae and the white mulberry root bark can be effectively used for preventing and treating obesity is found out for the first time, and significant effects can be generated. The fact that the composition can be used for effectively treating the hyperhomocysteinemia is also found out, and a new selection is provided for the treatment of the obesity and the hyperhomocysteinemia.

The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of hyperhomocysteinemia that are identified, wherein elevated levels of hyperhomocysteinemia are highly associated with PCV of the human eyes. In addition, the present invention further provides a method for detecting and diagnosing PCV of the human eyes.

The invention discloses a construction method of a neural tube defect model. The construction method comprises the following steps of step 1, collecting artificially inseminated eggs, cleaning the eggs, and putting the eggs in an incubator for incubation; step 2, performing incubation on the eggs until neural plates of chicken embryos start to close, adopting a chicken embryo neural groove injection method to inject homocysteine thiolactone into the eggs; and step 3, performing continuous incubation on the treated eggs, observing phenotypes of the chicken embryos, and screening a successful neural tube defect model. On the other hand, the invention also discloses application of the construction method in studying pathogenesis of neural tube defects caused by hyperhomocysteinemia. By adopting the construction method of the neural tube defect model, the deformity rate of a nervous system reaches 50 percent, the survival rate of the embryos reaches up to 87.5 percent, and the constructionmethod is a best model making method of observing the neural tube defects at present.

The invention relates to a pharmaceutical composition containing a pharmaceutical dose of dimethyldiguanide, folic acid, vitamin B12 and a pharmaceutical carrier or an excipient, belonging to the field of pharmacy. According to the pharmaceutical composition, a harmful result caused by adverse reaction of gastrointestinal tracts when dimethyldiguanide is singly used can be overcome; meanwhile, the pharmaceutical composition has the purpose of preventing, delaying or treating hyperhomocysteinemia, the effect is superior to the effects of existing similar pharmaceutical compositions, and the economic and practical pharmaceutical composition is provided for diabetic patients. The pharmaceutical composition further has the advantage that the medication compliance of the patients is improved.

The invention relates to a drug composition containing indapamide and statins and an application thereof in preparing drugs for treating the HHCY-hyperhomocysteinemia or the elevated homocysteine. The composition of the indapamide and the statins can further reduce the Hcy level, and the effect is superior to that of single drug, so that the composition of the indapamide and the statins can not only lower the Hcy level, but also has synergetic effect on reducing the Hcy damages. The composition of the invention is a selection for treating Hcy, which provides a more effective treatment protocol for treating high homocysteine. The invention belongs to the pharmaceutical field.

The invention relates to a novel application of 2,3,5,4-tetrahydroxy-stilbene-2-O-beta-D-Glucoside (TSG) in preventing and/or treating hyperhomocysteinemia (HHcy). The invention discloses pharmacologic actions of TSG which can remarkably relax superior mesenteric arteries of rats, inhibit homocysteine induced B type endothelin receptor up-regulation and inhibit activation of mitogen-activated protein kinase/nuclear factor kB/B type endothelin receptor signal axes so as to significantly treat the HHcy, and the blank that no drugs for treating the HHcy exist clinically is filled up.

The invention discloses a traditional Chinese medicine extract for treating hyperhomocysteinemia and preventing myocardial infarction and cerebral infarction, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 20 to 30 parts of radix astragali seu hedysari, 15 to 20 parts of Chinese angelica root, 8 to 20 parts of fructus gardeniae and 18 to 25 parts of Anhua dark tea. A preparation method of the traditional Chinese medicine composition comprises the following steps of: (1) extracting immersion liquid: mixing the radix astragali seu hedysari, the Chinese angelica root, the fructus gardeniae and water, heating and extracting at constant temperature to obtain a water extracting solution A1; mixing the Anhua dark tea and a certain amount of water, heating and extracting to obtain a water extracting solution B1; (2) filtering: filtering the water extracting solutions A1 and B1 obtained in the step S1 through a filtering membrane to obtain water extracting fine filtrate A2 and B2; (3) oxidizing: heating the water extracting fine filtrate A2 obtained in the step S2 and introducing oxygen to obtain an oxidized solution A3; (4) mixing: uniformly mixing the B2 obtained in the step S2 and the A3 obtained in the step S3 to obtain a mixed solution AB; and (5) bottling and sterilizing.

The invention discloses a case that caffeic acid can inhibit homocysteine induced leucocyte non-receptor tyrosine kinase Scr activation, and can further inhibit a PI3K/Akt signal pathway, the leucocyte adhesion molecule integrin beta2 expression, and the hyperhomocysteinemia induced rolling and adherence of leucocytes in leptomeningeal venules of mice, so the caffeic acid can control the hyperhomocysteinemia initiated cerebrovascular disease degeneration diseases.